FHIR © HL7.org  |  Server Home  |  Health Intersections FHIR Server v1.0.275  |  FHIR Version 4.0.0  | User: ANONYMOUS (Unknown)  

History Record

XML or JSON representation

Links: First Previous Next Last  (1 found). Search: http://test.fhir.org/r4/MedicinalProductIndication/_history?&_prior=2019-03-22T03:47:05.031Z&_format=text/xhtml&history-id=929d7c2b-8c55-4365-b3e0-71251de3a1 

Unknown message MedicinalProductIndication "example" Version "1"

Tags: (no tags)  +

This Resource , XML or JSON representation, or the full version history.. provenance for this resource
Updated: by

Generated Narrative with Details

id: example

diseaseSymptomProcedure: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip\nor knee replacement surgery.\nPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation\n(NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age\n≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).\nTreatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent\nDVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). (Details : {http://ema.europa.eu/example/indicationasdisease-symptom-procedure code 'Venousthromboembolismprophylaxis' = 'Venousthromboembolismprophylaxis)

comorbidity: Hipsurgery (Details : {http://ema.europa.eu/example/comorbidity code 'Hipsurgery' = 'Hipsurgery)

intendedEffect: PRYLX (Details : {http://ema.europa.eu/example/intendedeffect code 'PRYLX' = 'PRYLX)

population:


{
  "resourceType" : "MedicinalProductIndication",
  "id" : "example",
  "meta" : {
    "versionId" : "1",
    "lastUpdated" : "2019-01-13T15:33:32.390Z"
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative with Details</b></p><p><b>id</b>: example</p><p><b>diseaseSymptomProcedure</b>: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip\\nor knee replacement surgery.\\nPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation\\n(NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age\\n&#8805; 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class &#8805; II).\\nTreatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent\\nDVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). <span>(Details : {http://ema.europa.eu/example/indicationasdisease-symptom-procedure code 'Venousthromboembolismprophylaxis' = 'Venousthromboembolismprophylaxis)</span></p><p><b>comorbidity</b>: Hipsurgery <span>(Details : {http://ema.europa.eu/example/comorbidity code 'Hipsurgery' = 'Hipsurgery)</span></p><p><b>intendedEffect</b>: PRYLX <span>(Details : {http://ema.europa.eu/example/intendedeffect code 'PRYLX' = 'PRYLX)</span></p><p><b>population</b>: </p></div>"
  },
  "diseaseSymptomProcedure" : {
    "coding" : [
      {
        "system" : "http://ema.europa.eu/example/indicationasdisease-symptom-procedure",
        "code" : "Venousthromboembolismprophylaxis"
      }
    ],
    "text" : "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip\\nor knee replacement surgery.\\nPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation\\n(NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age\\n≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).\\nTreatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent\\nDVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients)."
  },
  "comorbidity" : [
    {
      "coding" : [
        {
          "system" : "http://ema.europa.eu/example/comorbidity",
          "code" : "Hipsurgery"
        }
      ]
    }
  ],
  "intendedEffect" : {
    "coding" : [
      {
        "system" : "http://ema.europa.eu/example/intendedeffect",
        "code" : "PRYLX"
      }
    ]
  },
  "population" : [
    {
      "ageRange" : {
        "low" : {
          "value" : 18,
          "unit" : "a"
        }
      }
    }
  ]
}